Minoxidil

• •Early shedding in weeks 2-8: minoxidil pushes resting follicles into a new cycle, so older hairs fall out before new ones grow in. It is temporary and usually a sign the drug is working -- do not stop.

• •Regrowth is slow. Give it at least 4 months of consistent daily use before judging, with peak benefit around 12 months.

• •It is maintenance, not a cure. Stop and gains are typically lost within 3-6 months as hair returns to its untreated trajectory.

• •Best response is on the crown (vertex); frontal and temple recession responds less.

• •Roughly a third of users respond poorly, likely due to low follicular sulfotransferase activity [PMID:34159872].

Beginner Protocol

Intermediate Protocol

Advanced Protocol

Minoxidil is one of the most extensively studied hair-loss treatments, with multiple randomized, double-blind, placebo-controlled trials.

Topical, men: In 393 men with androgenetic alopecia, 5% solution twice daily was significantly superior to 2% and placebo, producing roughly 45% more non-vellus hair regrowth than 2% at 48 weeks, with an earlier response and no systemic effects [PMID:12196747].

Topical, women: In 381 women with female pattern hair loss, both 5% and 2% beat placebo on hair count, and 5% was superior to 2% on patient-assessed benefit [PMID:15034503]. A separate randomized trial in 113 women showed once-daily 5% foam is non-inferior to twice-daily 2% solution with less itching and dandruff [PMID:21700360].

Oral (off-label): A 2024 double-blind randomized trial in 90 men found oral minoxidil 5 mg/day was NOT superior to topical 5% twice daily over 24 weeks; the most common oral side effects were hypertrichosis (49%) and headache (14%) [PMID:38598226]. A review of 17 studies (634 patients) concluded low-dose oral minoxidil is an effective, well-tolerated alternative for patients who struggle with topical [PMID:32622136], and a 1404-patient multicenter study documented its safety profile [PMID:33639244]. A 2025 international modified-Delphi consensus of 43 hair specialists standardized off-label dosing, contraindications, and monitoring [PMID:39565602].

Mechanism work: minoxidil is a prodrug activated by follicular sulfotransferase to minoxidil sulfate, a K-ATP channel opener that acts directly on the follicle root sheath [PMID:7689077][PMID:34159872].

Bottom line: strong, replicated human evidence supports topical minoxidil for male and female pattern hair loss; evidence for off-label low-dose oral minoxidil is growing but less definitive.

Topical (most common, usually mild):

• Scalp irritation, itching, dryness, flaking/dandruff -- more with the propylene-glycol solution than the foam [PMID:21700360].
• Temporary increased shedding in the first 2-8 weeks.
• Unwanted facial or body hair (hypertrichosis), especially in women, often from product migration or some systemic absorption.
• Rare: allergic contact dermatitis (can be to propylene glycol). Topical minoxidil showed no evidence of systemic effects in controlled trials [PMID:12196747][PMID:15034503].

Oral low-dose minoxidil (off-label; dose-related, systemic):

• Hypertrichosis is the most common effect (~15% in a 1404-patient cohort and the leading reason for discontinuation) [PMID:33639244].
• Lightheadedness, fluid retention/edema, tachycardia, headache, periorbital edema, and insomnia -- each occurred in under 2% and rarely required stopping [PMID:33639244].
• No life-threatening events were seen in that large cohort. At full antihypertensive doses (not hair-loss doses), oral minoxidil carries an FDA boxed warning for pericardial effusion (which can progress to tamponade) and reflex tachycardia; these are not seen at the low doses used for hair in supervised use.